WO2007071777A3 - Immuno-rna-constructs - Google Patents
Immuno-rna-constructs Download PDFInfo
- Publication number
- WO2007071777A3 WO2007071777A3 PCT/EP2006/070116 EP2006070116W WO2007071777A3 WO 2007071777 A3 WO2007071777 A3 WO 2007071777A3 EP 2006070116 W EP2006070116 W EP 2006070116W WO 2007071777 A3 WO2007071777 A3 WO 2007071777A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immuno
- constructs
- rna
- subject
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
Subject of the invention is a compound, consisting of a targeting moiety which specifically binds to a disease related cell surface marker, a nucleic acid which specifically induces cell death and a linker, wherein the linker covalently links the targeting moiety to the nucleic acid. Subject of the invention are also medicaments comprising the compound and their use as a medicament for the treatment of diseases, including proliferative diseases.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK06841574.4T DK1976564T3 (en) | 2005-12-21 | 2006-12-21 | Immuno-RNA-constructs |
EP06841574.4A EP1976564B1 (en) | 2005-12-21 | 2006-12-21 | Immuno-rna-constructs |
US12/086,817 US8829178B2 (en) | 2005-12-21 | 2006-12-21 | Immuno-RNA-constructs |
CA2633776A CA2633776C (en) | 2005-12-21 | 2006-12-21 | Immuno-rna-constructs |
CN2006800479378A CN101340934B (en) | 2005-12-21 | 2006-12-21 | Immuno-RNA-constructs |
HK09103177.0A HK1123728A1 (en) | 2005-12-21 | 2009-04-03 | Immuno-rna-constructs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05112660A EP1800695A1 (en) | 2005-12-21 | 2005-12-21 | Immuno-RNA-constructs |
EP05112660.5 | 2005-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007071777A2 WO2007071777A2 (en) | 2007-06-28 |
WO2007071777A3 true WO2007071777A3 (en) | 2007-11-22 |
Family
ID=36646002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/070116 WO2007071777A2 (en) | 2005-12-21 | 2006-12-21 | Immuno-rna-constructs |
Country Status (7)
Country | Link |
---|---|
US (1) | US8829178B2 (en) |
EP (2) | EP1800695A1 (en) |
CN (1) | CN101340934B (en) |
CA (1) | CA2633776C (en) |
DK (1) | DK1976564T3 (en) |
HK (1) | HK1123728A1 (en) |
WO (1) | WO2007071777A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9085622B2 (en) | 2010-09-03 | 2015-07-21 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101489383A (en) * | 2006-06-01 | 2009-07-22 | 杜克大学 | Delivery method |
US10842642B2 (en) | 2009-04-16 | 2020-11-24 | Nuvasive, Inc. | Methods and apparatus of performing spine surgery |
US20130245102A1 (en) * | 2010-10-12 | 2013-09-19 | Research Foundation Of The City University Of New York | Novel dna templates for small rna production in mammalian cells |
US9034839B2 (en) | 2012-04-20 | 2015-05-19 | Aptamir Therapeutics, Inc. | miRNA modulators of thermogenesis |
US20150216892A1 (en) * | 2012-08-03 | 2015-08-06 | Aptamir Therapeutics, Inc. | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders |
WO2014030147A2 (en) * | 2012-08-23 | 2014-02-27 | Fundación Fraunhofer Chile Research | Synthetic proteins based on dendrimers |
US10711272B2 (en) | 2014-01-21 | 2020-07-14 | City Of Hope | CTLA-4 aptamer siRNA species |
US10687956B2 (en) | 2014-06-17 | 2020-06-23 | Titan Spine, Inc. | Corpectomy implants with roughened bioactive lateral surfaces |
EP3735990A1 (en) * | 2014-12-09 | 2020-11-11 | Abbvie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
TWI726940B (en) | 2015-11-20 | 2021-05-11 | 美商泰坦脊柱股份有限公司 | Processes for additively manufacturing orthopedic implants |
CN108472730A (en) | 2015-11-20 | 2018-08-31 | 泰坦脊椎公司 | The processing of increasing material manufacturing orthopaedics implant |
LT3458479T (en) | 2016-06-08 | 2021-02-25 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
AU2017305136A1 (en) | 2016-08-03 | 2019-02-07 | Titan Spine, Inc. | Titanium implant surfaces free from alpha case and with enhanced osteoinduction |
UY39610A (en) | 2021-01-20 | 2022-08-31 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739350A (en) * | 1990-04-25 | 1998-04-14 | Pharmacia & Upjohn Company | CC-1065 analogs |
WO1998041648A2 (en) * | 1997-03-20 | 1998-09-24 | Variagenics, Inc. | Target genes for allele-specific drugs |
WO2002094185A2 (en) * | 2001-05-18 | 2002-11-28 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20030104985A1 (en) * | 2001-05-18 | 2003-06-05 | Jasenka Matulic-Adamic | Conjugates and compositions for cellular delivery |
WO2004044141A2 (en) * | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Conjugated oligomeric compounds and their use in gene modulation |
WO2005040379A2 (en) * | 2003-10-23 | 2005-05-06 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2005042558A1 (en) * | 2003-10-30 | 2005-05-12 | Aegera Therapeutics, Inc. | Iap nucleobase oligomers and oligomeric complexes and uses thereof |
US20050153915A1 (en) * | 2001-05-18 | 2005-07-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA) |
US20050159381A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA) |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
US20050176024A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA) |
EP1741781A2 (en) * | 2002-02-20 | 2007-01-10 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
WO2007056153A2 (en) * | 2005-11-04 | 2007-05-18 | Nastech Pharmaceutical Company Inc. | Peptide-dicer substrate rna conjugates as delivery vehicles for sirna |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
GB9200417D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
US5439819A (en) | 1993-08-27 | 1995-08-08 | The Regents Of The University Of California | Chimeric protein tyrosine kinases |
US5583034A (en) * | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
US5935835A (en) | 1996-10-11 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotide encoding human Myt-1 kinase clone |
US6346406B1 (en) * | 1997-08-20 | 2002-02-12 | University Of Medicine & Dentistry Of New Jersey | Elongation factor-2 kinase (EF-2 kinase), and methods of use therefor |
US7138103B2 (en) | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
WO2001001137A1 (en) | 1999-06-30 | 2001-01-04 | Children's Medical Center Corporation | Fusion protein and uses thereof |
IL151910A0 (en) * | 2000-04-12 | 2003-04-10 | Implyx Ltd | Compositions for drug delivery |
EP1283719B1 (en) | 2000-04-22 | 2007-09-05 | PharmedArtis GmbH | Apoptotic agents |
US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
JP2004535202A (en) | 2001-07-17 | 2004-11-25 | リサーチ ディベロップメント ファンデーション | Therapeutic agents containing pro-apoptotic proteins |
WO2003069306A2 (en) | 2002-02-13 | 2003-08-21 | Medbridge, Inc. | Protein carrier system for therapeutic oligonucleotides |
AU2003267423A1 (en) | 2002-10-03 | 2004-04-23 | Ecole Polytechnique Federale De Lausanne (Epfl) | Protein labelling with 06-alkylguanine-DNA alkyltransferase |
US20040204377A1 (en) | 2002-11-26 | 2004-10-14 | University Of Massachusetts | Delivery of siRNAs |
WO2004078215A2 (en) | 2003-02-28 | 2004-09-16 | The Board Of Trustees Of The University Of Illinois | Use of antibody conjugated deoxycytidine kinase for adept |
CN1826527B (en) | 2003-05-23 | 2010-11-24 | 瑞士联邦理工大学.洛桑(Epfl) | Methods for protein labeling based on acyl carrier protein |
US20050234000A1 (en) | 2003-12-12 | 2005-10-20 | Mitchell Gordon S | SiRNA delivery into mammalian nerve cells |
US8163479B2 (en) | 2004-03-02 | 2012-04-24 | Ecole Polytechnique Federale De Lausanne | Specific substrates for O6-alkylguanine-DNA alkyltransferase |
WO2005111238A2 (en) * | 2004-04-19 | 2005-11-24 | Archemix Corporation | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides |
WO2006021553A1 (en) | 2004-08-23 | 2006-03-02 | Covalys Biosciences Ag | Method for protein purification and labeling based on a chemoselective reaction |
EP1874738B1 (en) | 2005-04-27 | 2016-06-29 | Covalys Biosciences AG | Pyrimidines reacting with o6-alkylguanine-dna alkyltransferase |
EP1882688A1 (en) | 2006-07-25 | 2008-01-30 | EPFL Ecole Polytechnique Fédérale de Lausanne | Labelling of fusion proteins with synthetic probes |
-
2005
- 2005-12-21 EP EP05112660A patent/EP1800695A1/en not_active Withdrawn
-
2006
- 2006-12-21 CN CN2006800479378A patent/CN101340934B/en not_active Expired - Fee Related
- 2006-12-21 WO PCT/EP2006/070116 patent/WO2007071777A2/en active Application Filing
- 2006-12-21 US US12/086,817 patent/US8829178B2/en not_active Expired - Fee Related
- 2006-12-21 DK DK06841574.4T patent/DK1976564T3/en active
- 2006-12-21 EP EP06841574.4A patent/EP1976564B1/en not_active Not-in-force
- 2006-12-21 CA CA2633776A patent/CA2633776C/en not_active Expired - Fee Related
-
2009
- 2009-04-03 HK HK09103177.0A patent/HK1123728A1/en not_active IP Right Cessation
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739350A (en) * | 1990-04-25 | 1998-04-14 | Pharmacia & Upjohn Company | CC-1065 analogs |
WO1998041648A2 (en) * | 1997-03-20 | 1998-09-24 | Variagenics, Inc. | Target genes for allele-specific drugs |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
US20030104985A1 (en) * | 2001-05-18 | 2003-06-05 | Jasenka Matulic-Adamic | Conjugates and compositions for cellular delivery |
US20050153915A1 (en) * | 2001-05-18 | 2005-07-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA) |
US20050159381A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA) |
WO2002094185A2 (en) * | 2001-05-18 | 2002-11-28 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20050176024A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA) |
EP1741781A2 (en) * | 2002-02-20 | 2007-01-10 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
WO2004044141A2 (en) * | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Conjugated oligomeric compounds and their use in gene modulation |
WO2005040379A2 (en) * | 2003-10-23 | 2005-05-06 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2005042558A1 (en) * | 2003-10-30 | 2005-05-12 | Aegera Therapeutics, Inc. | Iap nucleobase oligomers and oligomeric complexes and uses thereof |
WO2007056153A2 (en) * | 2005-11-04 | 2007-05-18 | Nastech Pharmaceutical Company Inc. | Peptide-dicer substrate rna conjugates as delivery vehicles for sirna |
Non-Patent Citations (7)
Title |
---|
CASSIDAY L. A. ET AL.: "Yeast genetic selections to optimize RNA decoys for transcription factor NF-kB", PNAS, vol. 100, no. 7, 1 April 2003 (2003-04-01), pages 3930 - 3935, XP007902933 * |
CHIU Y. L. ET AL.: "Visualizing a Correlation between siRNA Localization, Cellular Uptake and RNAi in living Cells", CHEMISTRY AND BIOLOGY, vol. 11, August 2004 (2004-08-01), pages 1165 - 1175, XP008066695 * |
DYKXHOORN D M ET AL: "KILLING THE MESSENGER: SHORT RNAS THAT SILENCE GENE EXPRESSION", NATURE REVIEWS MOLECULAR CELL BIOLOGY, MACMILLAN MAGAZINES, LONDON, GB, vol. 4, no. 6, June 2003 (2003-06-01), pages 457 - 467, XP009013985 * |
LORENZ C ET AL: "Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 19, 4 October 2004 (2004-10-04), pages 4975 - 4977, XP004548799, ISSN: 0960-894X * |
SELZER E ET AL: "N-ras inhibits apoptosis in human melanoma grown in SCID mice by reciprocal regulation of BCL-2 and the BCL-2 associated protein bax", RADIOTHERAPY AND ONCOLOGY, ELSEVIER, vol. 40, 1996, pages S48, XP004999651, ISSN: 0167-8140 * |
SONG E. ET AL.: "Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors", NATURE BIOTECHNOLOGY, vol. 23, no. 6, 6 June 2005 (2005-06-06), pages 709 - 717, XP002390626 * |
SOUTSCHEK JUERGEN ET AL: "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 432, no. 7014, 11 November 2004 (2004-11-11), pages 173 - 178, XP002333747, ISSN: 0028-0836 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9085622B2 (en) | 2010-09-03 | 2015-07-21 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
Also Published As
Publication number | Publication date |
---|---|
EP1800695A1 (en) | 2007-06-27 |
HK1123728A1 (en) | 2009-06-26 |
US8829178B2 (en) | 2014-09-09 |
WO2007071777A2 (en) | 2007-06-28 |
CN101340934B (en) | 2013-04-24 |
US20090304717A1 (en) | 2009-12-10 |
EP1976564A2 (en) | 2008-10-08 |
EP1976564B1 (en) | 2016-02-24 |
DK1976564T3 (en) | 2016-06-06 |
CN101340934A (en) | 2009-01-07 |
CA2633776C (en) | 2018-03-06 |
CA2633776A1 (en) | 2007-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007071777A3 (en) | Immuno-rna-constructs | |
WO2010066684A3 (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
WO2006079120A3 (en) | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use | |
WO2010001169A3 (en) | Chemical compounds 251 | |
WO2006060533A3 (en) | Conjugates of 1, 8-bis-naphthalimides with an antibody | |
IN2012DN03025A (en) | ||
WO2007112193A3 (en) | Camptothecin-binding moiety conjugates | |
WO2009100194A3 (en) | Camptothecin-binding moiety conjugates | |
WO2007064345A3 (en) | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | |
WO2005097135A3 (en) | Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives | |
WO2007131238A8 (en) | Compounds and methods for modulating expression apob | |
WO2008036841A3 (en) | Tripartite oligonucleotide complexes and methods for gene silencing by rna interference | |
WO2012075040A3 (en) | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES | |
WO2009053041A3 (en) | Identification of tumor-associated markers for diagnosis and therapy | |
WO2007071963A3 (en) | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | |
WO2006029081A3 (en) | Nucleoside-lipid conjugates, their method of preparation and uses thereof | |
WO2007093880A3 (en) | Novel pyrone-indole derivatives and process for their preparation | |
WO2008076954A3 (en) | Heterocycle compounds and methods of use thereof | |
WO2007009724A3 (en) | Cycloalkane-substituted pyrazoline derivatives, their preparation and use as medicaments | |
WO2010136508A3 (en) | Stem cell targeting | |
WO2011038933A3 (en) | Anti-hsv antibody | |
WO2009003719A3 (en) | Indane-amine derivatives, their preparation and use as medicaments | |
EA200801425A1 (en) | DIAZEPINONY | |
WO2007009686A3 (en) | Substituted pyrazoline compounds, their preparation and use as medicaments | |
WO2005120577A3 (en) | Derivatives of chemotherapeutic agents with a formaldehyde releasing moeity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680047937.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2633776 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006841574 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12086817 Country of ref document: US |